GlassScriptPhysician profile
Charles Vandenberg
NPI 1750638516
$2,212.23
in general payments reported to CMS, 2019-2025
31 companies · $13.76 in 2025
The $13.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $67.48 · 2021: $44.31 · 2022: $155 · 2023: $610 · 2024: $342 · 2025: $13.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.88 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $347.32 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $290.01 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $198.21 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $180.47 | 2019-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $139.28 | 2019-2025 | Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.07 | 2019-2022 | |
| Astellas Pharma US INC | $96.51 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $82.12 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $79.14 | 2022-2023 | |
| Exact Sciences Corporation | $67.81 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $61.18 | 2019-2022 | |
| Myriad Women'S Health, INC. | $51.68 | 2023 | Myrisk |
| Amgen INC. | $51.16 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $48.61 | 2019 | |
| Alkermes, INC. | $45.54 | 2024 | Aristada, Vivitrol, Lybalvi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.15 | 2019-2024 | Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $37.42 | 2019-2021 | |
| Axsome Therapeutics, INC. | $36.76 | 2024 | Auvelity |
| Mallinckrodt Enterprises LLC | $27.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.48 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $21.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.50 | 2019 | |
| Mylan Specialty L.P. | $16.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.67 | 2023 | Voquezna |
| Amarin Pharma, INC. | $16.19 | 2020 | |
| Halozyme INC | $16.05 | 2023 | |
| Shire North American Group INC | $15.09 | 2019 | |
| Allergan, INC. | $14.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.30 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.05 | 2022 | |
| Circassia INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Vandenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.